In the early stages of the race to develop Covid-19 vaccines, it wasn’t clear how many would work, which manufacturers would score successes, or which projects would fall by the wayside.
Now, just a few days past the first anniversary of the start of Moderna’s Phase 1 trial — the first to begin in the United States — we have a much clearer picture of the Covid vaccine landscape.
